EUVIMEDEUVIMED entdecken
Crossref

Hemodynamic and Mid-Term Outcomes for Transcatheter Aortic Valve Replacement in Degenerated Internally Stented Valves

Ahmed AlBadri, Jubin Joseph, Vivek Patel, Dhairya Patel, Ofir Koren, Wen Cheng, Hasan Jilaihawi, Raj Makkar

JACC: Cardiovascular Interventions · 2023

DOI: 10.1016/j.jcin.2023.01.381 ↗

Kurz gefasst

Fachartikel in der Zeitschrift JACC: Cardiovascular Interventions, 2023. Verfasst von Ahmed AlBadri und 7 weiteren Autor:innen. Beteiligte Einrichtung: Smidt Heart Institute, Cedars-Sinai Medical Center, Los Angeles, California, USA. Hauptthemen laut MEDLINE: Transcatheter Aortic Valve Replacement, Aortic Valve Stenosis, Heart Valve Prosthesis, Bioprosthesis. Die Arbeit wurde bisher 10-mal zitiert (Crossref) und nennt 38 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

BACKGROUND: Valve-in-valve (ViV) transcatheter aortic valve replacement is indicated in patients undergoing repeat intervention for degenerative aortic valve bioprostheses. Patients with internally stented valves (ie, Mitroflow and Trifecta) are at high risk for coronary artery obstruction during ViV procedures because of valve design, as the leaflets are mounted outside the valve stent. OBJECTIVES: The aim of this study was to compare the hemodynamic and clinical outcomes of transcatheter aortic valve replacement within internally stented valves (ViV-IS) vs other surgical valves (ViV-OS). METHODS: Baseline characteristics, hemodynamic parameters, and clinical outcomes of patients who underwent ViV-IS were retrospectively collected and compared with those of patients who underwent ViV-OS. RESULTS: A total of 250 patients (65% men, median Society of Thoracic Surgeons score 4.4% [IQR: 2.2%-8.4%]) were included. Seventy-one patients (28%) underwent ViV-IS, and 179 (72%) patients underwent ViV-OS. Patients who underwent ViV-OS had better periprocedural hemodynamic status compared with those who underwent ViV-IS (median mean gradient 6 [IQR: 2-13] vs 12 [IQR: 6-16]; P < 0.001). This was not significantly different when both groups were matched on the basis of age, sex, and valve internal diameter size (median mean gradient: 18 [IQR: 13-25] for ViV-OS vs 18 [IQR: 11-24] for ViV-IS; P = 0.36). Coronary protection for potential occlusion was performed more in ViV-IS vs ViV-OS pr (79% vs 6%, respectively; P < 0.001). Patients who underwent ViV-IS had a higher risk for coronary occlusion, requiring stent deployment, compared with those who underwent ViV-OS (54% vs 3%, respectively; P < 0.001. There was no difference in mortality at 3 years between the 2 groups (P = 0.59). CONCLUSIONS: Patients who underwent ViV-IS had a very high incidence of coronary compromise that can be safely and effectively treated. In the setting of a systematic coronary protection strategy, ViV-OS and ViV-IS provide similar mid-term outcome, and periprocedural hemodynamic status (following adjustment for age, sex, and true internal diameter).

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Transcatheter Aortic Valve ReplacementAortic Valve StenosisHeart Valve ProsthesisBioprosthesisCoronary OcclusionHeart Valve Prosthesis ImplantationMaleHumansFemaleAortic ValveRetrospective StudiesTreatment OutcomeProsthesis FailureProsthesis DesignHemodynamicsStents

Stichwörter der Autor:innen

MitroflowTAVRTrifectacoronary obstructioninternally stented valvesoutcome

Autor:innen und Institutionen

  • Smidt Heart Institute, Cedars-Sinai Medical Center, Los Angeles, California, USA.
  • Smidt Heart Institute, Cedars-Sinai Medical Center, Los Angeles, California, USA. Electronic address: raj.makkar@cshs.org.

Zitieren

APA

AlBadri, A., Joseph, J., Patel, V., Patel, D., Koren, O., Cheng, W., Jilaihawi, H., & Makkar, R. (2023). Hemodynamic and Mid-Term Outcomes for Transcatheter Aortic Valve Replacement in Degenerated Internally Stented Valves. JACC: Cardiovascular Interventions. https://doi.org/10.1016/j.jcin.2023.01.381

Vancouver

AlBadri A, Joseph J, Patel V, Patel D, Koren O, Cheng W, et al. Hemodynamic and Mid-Term Outcomes for Transcatheter Aortic Valve Replacement in Degenerated Internally Stented Valves. JACC: Cardiovascular Interventions. 2023. doi:10.1016/j.jcin.2023.01.381

BibTeX
@article{AlBadri2023,
  author = {AlBadri, Ahmed and Joseph, Jubin and Patel, Vivek and Patel, Dhairya and Koren, Ofir and Cheng, Wen and Jilaihawi, Hasan and Makkar, Raj},
  title = {Hemodynamic and Mid-Term Outcomes for Transcatheter Aortic Valve Replacement in Degenerated Internally Stented Valves},
  journal = {JACC: Cardiovascular Interventions},
  year = {2023},
  doi = {10.1016/j.jcin.2023.01.381}
}
Kostenlos starten →